Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients

Table 2 Summary of patient characteristics

Characteristics	Responders (n = 12)	Non-responders (n = 12)	P value
Age – no. (%)
> 65	6 (50%)	2 (17%)	0.083
≤ 65	6 (50%)	10 (83%)
Sex – no. (%)
Male	9 (75%)	9 (75%)	>0.999
Female	3 (25%)	3 (25%)
LDH – no. (%)
> 1× ULN	1 (8%)	8 (67%)	0.0032
≤ 1× ULN	11 (92%)	4 (33%)
Disease volume – no. (%)
SPOD > 1000 mm²	7 (58%)	10 (83%)	0.178
SPOD ≤ 1000 mm²	5 (42%)	2 (17%)
AJCC tumor stage – no. (%)
M1a or M1b	6 (50%)	1 (8%)	0.025
M1c	6 (50%)	11 (92%)
Mutation – no. (%)
BRAF^V600E/K	3 (25%)	5 (42%)	0.3865
Non-BRAF^V600E/K	9 (75%)	7 (58%)

Abbreviations: LDH lactate dehydrogenase, SPOD sum of product of diameters, AJCC American Joint Committee on Cancer, ULN upper limit of normal. The p value was calculated using the Chi square test for a two by two contingency table

ISSN: 2050-7771